Cargando…

Naive T cells inhibit the outgrowth of intractable antigen-activated memory T cells: implications for T-cell immunotherapy

BACKGROUND: The wider application of T cells targeting viral tumor-antigens via their native receptors is hampered by the failure to expand potent tumor-specific T cells from patients. Here, we examine reasons for and solutions to this failure, taking as our model the preparation of Epstein-Barr vir...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharma, Sandhya, Woods, Mae, Mehta, Naren U, Sauer, Tim, Parikh, Kathan S, Schmueck-Henneresse, Michael, Zhang, Huimin, Mehta, Birju, Brenner, Malcolm K, Heslop, Helen E, Rooney, Cliona M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10124261/
https://www.ncbi.nlm.nih.gov/pubmed/37072346
http://dx.doi.org/10.1136/jitc-2022-006267
_version_ 1785029802053337088
author Sharma, Sandhya
Woods, Mae
Mehta, Naren U
Sauer, Tim
Parikh, Kathan S
Schmueck-Henneresse, Michael
Zhang, Huimin
Mehta, Birju
Brenner, Malcolm K
Heslop, Helen E
Rooney, Cliona M
author_facet Sharma, Sandhya
Woods, Mae
Mehta, Naren U
Sauer, Tim
Parikh, Kathan S
Schmueck-Henneresse, Michael
Zhang, Huimin
Mehta, Birju
Brenner, Malcolm K
Heslop, Helen E
Rooney, Cliona M
author_sort Sharma, Sandhya
collection PubMed
description BACKGROUND: The wider application of T cells targeting viral tumor-antigens via their native receptors is hampered by the failure to expand potent tumor-specific T cells from patients. Here, we examine reasons for and solutions to this failure, taking as our model the preparation of Epstein-Barr virus (EBV)-specific T cells (EBVSTs) for the treatment of EBV-positive lymphoma. EBVSTs could not be manufactured from almost one-third of patients, either because they failed to expand, or they expanded, but lacked EBV specificity. We identified an underlying cause of this problem and established a clinically feasible approach to overcome it. METHODS: CD45RO+CD45RA− memory compartment residing antigen-specific T cells were enriched by depleting CD45RA positive (+) peripheral blood mononuclear cells (PBMCs) that include naïve T cells, among other subsets, prior to EBV antigen stimulation. We then compared the phenotype, specificity, function and T-cell receptor (TCR) Vβ repertoire of EBVSTs expanded from unfractionated whole (W)-PBMCs and CD45RA-depleted (RAD)-PBMCs on day 16. To identify the CD45RA component that inhibited EBVST outgrowth, isolated CD45RA+ subsets were added back to RAD-PBMCs followed by expansion and characterization. The in vivo potency of W-EBVSTs and RAD-EBVSTs was compared in a murine xenograft model of autologous EBV+ lymphoma. RESULTS: Depletion of CD45RA+ PBMCs before antigen stimulation increased EBVST expansion, antigen-specificity and potency in vitro and in vivo. TCR sequencing revealed a selective outgrowth in RAD-EBVSTs of clonotypes that expanded poorly in W-EBVSTs. Inhibition of antigen-stimulated T cells by CD45RA+ PBMCs could be reproduced only by the naïve T-cell fraction, while CD45RA+ regulatory T cells, natural killer cells, stem cell memory and effector memory subsets lacked inhibitory activity. Crucially, CD45RA depletion of PBMCs from patients with lymphoma enabled the outgrowth of EBVSTs that failed to expand from W-PBMCs. This enhanced specificity extended to T cells specific for other viruses. CONCLUSION: Our findings suggest that naïve T cells inhibit the outgrowth of antigen-stimulated memory T cells, highlighting the profound effects of intra-T-cell subset interactions. Having overcome our inability to generate EBVSTs from many patients with lymphoma, we have introduced CD45RA depletion into three clinical trials: NCT01555892 and NCT04288726 using autologous and allogeneic EBVSTs to treat lymphoma and NCT04013802 using multivirus-specific T cells to treat viral infections after hematopoietic stem cell transplantation.
format Online
Article
Text
id pubmed-10124261
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-101242612023-04-25 Naive T cells inhibit the outgrowth of intractable antigen-activated memory T cells: implications for T-cell immunotherapy Sharma, Sandhya Woods, Mae Mehta, Naren U Sauer, Tim Parikh, Kathan S Schmueck-Henneresse, Michael Zhang, Huimin Mehta, Birju Brenner, Malcolm K Heslop, Helen E Rooney, Cliona M J Immunother Cancer Clinical/Translational Cancer Immunotherapy BACKGROUND: The wider application of T cells targeting viral tumor-antigens via their native receptors is hampered by the failure to expand potent tumor-specific T cells from patients. Here, we examine reasons for and solutions to this failure, taking as our model the preparation of Epstein-Barr virus (EBV)-specific T cells (EBVSTs) for the treatment of EBV-positive lymphoma. EBVSTs could not be manufactured from almost one-third of patients, either because they failed to expand, or they expanded, but lacked EBV specificity. We identified an underlying cause of this problem and established a clinically feasible approach to overcome it. METHODS: CD45RO+CD45RA− memory compartment residing antigen-specific T cells were enriched by depleting CD45RA positive (+) peripheral blood mononuclear cells (PBMCs) that include naïve T cells, among other subsets, prior to EBV antigen stimulation. We then compared the phenotype, specificity, function and T-cell receptor (TCR) Vβ repertoire of EBVSTs expanded from unfractionated whole (W)-PBMCs and CD45RA-depleted (RAD)-PBMCs on day 16. To identify the CD45RA component that inhibited EBVST outgrowth, isolated CD45RA+ subsets were added back to RAD-PBMCs followed by expansion and characterization. The in vivo potency of W-EBVSTs and RAD-EBVSTs was compared in a murine xenograft model of autologous EBV+ lymphoma. RESULTS: Depletion of CD45RA+ PBMCs before antigen stimulation increased EBVST expansion, antigen-specificity and potency in vitro and in vivo. TCR sequencing revealed a selective outgrowth in RAD-EBVSTs of clonotypes that expanded poorly in W-EBVSTs. Inhibition of antigen-stimulated T cells by CD45RA+ PBMCs could be reproduced only by the naïve T-cell fraction, while CD45RA+ regulatory T cells, natural killer cells, stem cell memory and effector memory subsets lacked inhibitory activity. Crucially, CD45RA depletion of PBMCs from patients with lymphoma enabled the outgrowth of EBVSTs that failed to expand from W-PBMCs. This enhanced specificity extended to T cells specific for other viruses. CONCLUSION: Our findings suggest that naïve T cells inhibit the outgrowth of antigen-stimulated memory T cells, highlighting the profound effects of intra-T-cell subset interactions. Having overcome our inability to generate EBVSTs from many patients with lymphoma, we have introduced CD45RA depletion into three clinical trials: NCT01555892 and NCT04288726 using autologous and allogeneic EBVSTs to treat lymphoma and NCT04013802 using multivirus-specific T cells to treat viral infections after hematopoietic stem cell transplantation. BMJ Publishing Group 2023-04-18 /pmc/articles/PMC10124261/ /pubmed/37072346 http://dx.doi.org/10.1136/jitc-2022-006267 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Clinical/Translational Cancer Immunotherapy
Sharma, Sandhya
Woods, Mae
Mehta, Naren U
Sauer, Tim
Parikh, Kathan S
Schmueck-Henneresse, Michael
Zhang, Huimin
Mehta, Birju
Brenner, Malcolm K
Heslop, Helen E
Rooney, Cliona M
Naive T cells inhibit the outgrowth of intractable antigen-activated memory T cells: implications for T-cell immunotherapy
title Naive T cells inhibit the outgrowth of intractable antigen-activated memory T cells: implications for T-cell immunotherapy
title_full Naive T cells inhibit the outgrowth of intractable antigen-activated memory T cells: implications for T-cell immunotherapy
title_fullStr Naive T cells inhibit the outgrowth of intractable antigen-activated memory T cells: implications for T-cell immunotherapy
title_full_unstemmed Naive T cells inhibit the outgrowth of intractable antigen-activated memory T cells: implications for T-cell immunotherapy
title_short Naive T cells inhibit the outgrowth of intractable antigen-activated memory T cells: implications for T-cell immunotherapy
title_sort naive t cells inhibit the outgrowth of intractable antigen-activated memory t cells: implications for t-cell immunotherapy
topic Clinical/Translational Cancer Immunotherapy
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10124261/
https://www.ncbi.nlm.nih.gov/pubmed/37072346
http://dx.doi.org/10.1136/jitc-2022-006267
work_keys_str_mv AT sharmasandhya naivetcellsinhibittheoutgrowthofintractableantigenactivatedmemorytcellsimplicationsfortcellimmunotherapy
AT woodsmae naivetcellsinhibittheoutgrowthofintractableantigenactivatedmemorytcellsimplicationsfortcellimmunotherapy
AT mehtanarenu naivetcellsinhibittheoutgrowthofintractableantigenactivatedmemorytcellsimplicationsfortcellimmunotherapy
AT sauertim naivetcellsinhibittheoutgrowthofintractableantigenactivatedmemorytcellsimplicationsfortcellimmunotherapy
AT parikhkathans naivetcellsinhibittheoutgrowthofintractableantigenactivatedmemorytcellsimplicationsfortcellimmunotherapy
AT schmueckhenneressemichael naivetcellsinhibittheoutgrowthofintractableantigenactivatedmemorytcellsimplicationsfortcellimmunotherapy
AT zhanghuimin naivetcellsinhibittheoutgrowthofintractableantigenactivatedmemorytcellsimplicationsfortcellimmunotherapy
AT mehtabirju naivetcellsinhibittheoutgrowthofintractableantigenactivatedmemorytcellsimplicationsfortcellimmunotherapy
AT brennermalcolmk naivetcellsinhibittheoutgrowthofintractableantigenactivatedmemorytcellsimplicationsfortcellimmunotherapy
AT heslophelene naivetcellsinhibittheoutgrowthofintractableantigenactivatedmemorytcellsimplicationsfortcellimmunotherapy
AT rooneyclionam naivetcellsinhibittheoutgrowthofintractableantigenactivatedmemorytcellsimplicationsfortcellimmunotherapy